Clinical trials: Muscle Tumor
Dupuytren's Contracture
DEPART Study at Yale
This is a randomized study to determine whether radiation therapy reduces the risk of progression / recurrence of Dupuytren's disease / contracture.
- Trial name
- Dupuytren's (NCT07661342)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Yale University
Muscle-Invasive Bladder Carcinoma
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
Invasive bladder cancer is managed with neoadjuvant therapy followed by bladder removal (cystectomy). Research shows that approximately 40% of patient will have no remaining cancer left in their bladder after completion of the…
- Trial name
- NEO-BLAST (NCT06537154)
- Testing
- Active Surveillance, Control arm - Definitive bladder treatment
- Where
- Canada
- Volunteers
- 688 people
- Sponsor
- Peter Black
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Soft Tissue Sarcoma, Bone Sarcoma
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT…
- Trial name
- ImmunoSarc (NCT03277924)
- Testing
- Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin
- Where
- 13 sites in Italy, Spain and 1 more
- Volunteers
- 197 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Uterine Fibroids
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.
- Trial name
- NCT01452659
- Testing
- TAK-385
- Where
- 27 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Takeda
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Stage IV Non-small Cell Lung Cancer, Cachexia
Ruxolitinib for Cancer Cachexia
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
- Trial name
- NCT04906746
- Testing
- Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients.
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tu Dan
Carcinoma in Situ of Bladder
Retrospective Chart Review of Valstar
This is an observational study involving a retrospective review of medical records of adult patients who have been treated with intravesical valrubicin for bladder carcinoma in situ (CIS) since October 2009.
- Trial name
- NCT01304173
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Sarcoma, Advanced Sarcoma
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
- Conditions
- Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma
- Trial name
- NCT04242238
- Testing
- DCC-3014, Avelumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Adult Solid Tumor
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical…
- Trial name
- NCT06059547
- Testing
- Nivolumab, Visugromab (CTL-002)
- Where
- 4 sites in Italy
- Volunteers
- 31 people
- Sponsor
- CatalYm GmbH
Sarcopenia, Paclitaxel Induced Neuropathy
Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)
This prospective observational study aims to investigate the relationship between sarcopenia and the development of paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer.
- Conditions
- Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
- Trial name
- Neuro-Sarc (NCT06996548)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Gazi University
Breast Cancer
Transversus Thoracic Muscle Plane Combined With Pectoral Nerves Block for Breast Cancer Surgery
This is a prospective, randomized, controlled trial for evaluating the efficacy of addition of transversus thoracic muscle plane block to pectoral nerves block versus pectoral nerves block for quality of recovery scores in breast…
- Trial name
- NCT05448638
- Testing
- the combination of transversus thoracic muscle plane and pectoral nerves blocks, the pectoral nerves block only
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Zhejiang Cancer Hospital
Lax Skin
Treatment for Lifting Upper Arm Lax Skin
Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.
- Trial name
- NCT05358327
- Testing
- Sofwave
- Where
- 4 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sofwave Medical LTD
Lipoma, Branchial Cleft Anomalies
Radiological Diagnosis of Pediatric Neck Swellings
Various diagnostic imaging modalities have been utilized in the assessment of pediatric neck lesions, including gray-scale and Doppler ultrasonography, conventional and three-dimensional computed tomography (CT), magnetic…
- Conditions
- Lipoma, Branchial Cleft Anomalies, Cystic Hygroma (Macro-cystic Lymphatic Malformation), Rhabdomyosarcoma
- Trial name
- NCT07734805
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Non-muscle-invasive Bladder Cancer
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
- Trial name
- POTOMAC (NCT03528694)
- Testing
- Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
- Where
- 120 sites in Australia, Austria and 10 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Enlarged Uterus, Adenomyosis
Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus
Enlarged uterus is frequently encountered in clinical practice, and its incidence due to conditions such as adenomyosis, uterine fibroids, and other gynecological disorders has steadily increased over the years statistically.
- Conditions
- Enlarged Uterus, Adenomyosis, Uterine Fibroids (UF)
- Trial name
- NCT06663553
- Testing
- TU-LESS, vNOTES
- Where
- China
- Volunteers
- 210 people
- Sponsor
- West China Second University Hospital
Superficial Bladder Cancer
Therapeutic Instillation of Mistletoe
The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence.
- Trial name
- TIM (NCT02106572)
- Testing
- abnobaVISCUM 900, Mitomycin C
- Where
- 5 sites in Egypt, Germany
- Volunteers
- 174 people
- Sponsor
- Abnoba Gmbh
Sarcopenia, Pediatric Cancer
Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
In children, both malnutrition and sarcopenia are associated with prolongation of hospital stay, increased morbidity, mortality, and health-related complications.
- Trial name
- NCT05294380
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Trakya University
Breast Neoplasms, Body Composition
Longitudinal Body Composition Assessment in Breast Cancer Patients
This observational cohort study aims to track longitudinal changes in body composition, including skeletal muscle mass and fat distribution, in patients diagnosed with breast cancer.
- Conditions
- Breast Neoplasms, Body Composition, Sarcopenia, Fat Redistribution
- Trial name
- NCT07472803
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.